[Edaily Reporter Kwon Oh Seok ] Macquarie Securities announced on the 4th that it has designated BHI Co., LTD.(083650)as a top pick within the sector, alongside DOOSAN ENERBILITY and HyundaiEngineering&Construction, as the U.S. nuclear power market moves beyond policy expectations into the actual order-winning phase. The firm maintained its “Buy” rating and set a target price of 107,000 won. BHI Co., LTD. logo. (Photo courtesy of BHI Co., LTD.) Lee Jae-seo, an analyst at Macquarie Securities, stated in a report titled “Korea Nuclear: From Narrative to Orders” “The U.S. nuclear power market is entering a substantive order cycle, not merely a policy cycle,” and analyzed that “the period from the second half of 2026 to the first half of 2027 will be a critical turning point where momentum in nuclear power investment shifts from expectations to actual orders.” The analyst noted, “The U.S. Department of Energy’s (DOE) $17.5 billion nuclear power supply chain loan program will serve as a key link connecting the industry’s vision with actual procurement,” and assessed that “since this program can provide funding for long-lead-time equipment for up to five projects even before a Final Investment Decision (FID) is made, it has the potential to accelerate the timing of major equipment procurement by up to three years.” Accordingly, the analyst identified DOOSAN ENERBILITY, HyundaiEngineering&Construction, and KoreaElectricPower (KEPCO) as beneficiary stocks. He explained, “BHI Co., LTD. has consistently secured orders for nuclear power plant balance-of-plant (BOP) equipment from Korea Hydro & Nuclear Power Co. for domestic nuclear power projects, including Shin-Kori Units 3 and 4,” adding, “Although the BOP business currently accounts for only about 5% of total revenue, a meaningful revaluation could occur as visibility across the entire nuclear power value chain improves.”
Bank of Korea Governor Shin Hyun-song predicted that next year’s consumer price inflation rate will exceed the previous forecast of 2.5%. He also forecast that economic growth rates for this year and …
Aptabio Therapeutics Inc.(293780)has expressed confidence ahead of the announcement of the efficacy of its kidney disease treatment candidate “Isuzinaxib” (APX-115). This follows the company’s selecti…
Kakao(035720)has revealed why it selected Amazon Web Services (AWS) as its core infrastructure partner for artificial intelligence (AI) model training. Kakao’s strategy is to flexibly secure graphics …